Objective To study the effect of signal-selective parathyroid hormone (PTH) analogue peptide on Wnt signal ing factors in osteoblasts isolated from neonatal mouse, and provide theoretical basis for the mechanism of PTH’s function in bone metabolism. Methods Osteoblasts were isolated from calvaria of 2-3-day-old C57BL neonatal mouse and identified by alkal ine phosphatase (ALP) staining, and Alizarin red staining. The cells at passage 1 were divided into 4 groups: control group, PTH (1-34) group, G1R19 (1-34) group, and G1R19 (1-28) group. Then the medium was changed to α-MEM supplemented with 1%FBS. After 12 hours, trifluoroacetic acid or three peptides [(10 nmol/L PTH (1-34), 10 nmol/L G1R19 (1-34), and 100 nmol/L G1R19 (1-28)] were added into the culture medium. After 4 hours, the cells were washed gently ithcold PBS 3 times before total RNA was isolated. The expressions of Wnt related genes were measured by quantitative eal-time PCR. Results Most of the cells were polygonal and triangular; the cells were positive for ALP staining with blue cytoplasm at 14 days and the Al izarin red staining showed the formation of red mineral ized nodules in the special mineral ization induction medium at 28 days. The expressions of osteocalcin mRNA and Wnt5b mRNA in PTH (1-34) group, G1R19 (1-34) group, and G1R19 (1-28) group were significantly higher than those in control group (P lt; 0.05); the expression of Wnt2 mRNA was significantly lower than that in control group (P lt; 0.05); the expression of β-catenin mRNA in PTH (1-34) group was significantly higher than that in control group (P lt; 0.05); the expression of Wnt7b mRNA in PTH (1-34) group and G1R19 (1- 34) group was higher than that in control group, and the G1R19 (1-34) group was higher than PTH (1-34) group and G1R19 (1-28) group (P lt; 0.05). Conclusion In the Wnt-related factors, PTH (1-34) and G1R19 (1-34) affect mainly canonical Wnt signal factors, but the G1R19 (1-28) chiefly acts on non-canonical Wnt signal factors.
Objective To investigate whether p38 mitogen activated protein kinase (p38MAPK) inhibitor can reduce acute lung injury (ALI) caused by lipopolysaccharide (LPS) by regulating Th17/Treg balance. Methods Balb/c mice were randomly divided into a control group, an ALI group and an intervention group. The mice in the control group were injected with phosphate-buffered saline, the mice in the ALI group were intraperitoneally injected with 40 mg/kg LPS, and the mice in the intervention group were injected with SB203580 (0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg) intraperitoneally 1 h prior to the intraperitoneal injection of LPS. All mice were killed on 12 h later respectively. Hematoxylin-eosinstin staining was used to observe the pathological changes of lung tissue, and cell classification, counting, and total protein levels in bronchoalveolar lavage fluid (BALF) were detected. Transcript expression of forkhead box p3 (Foxp3) and retinoic acid receptor-related orphan receptor-γt (RORγt) was detected by real-time polymerase chain reaction. Interleukin (IL)-6, IL-10, IL-17, IL-23 and transforming growth factor-β (TGF-β) in lung tissue and IL-6, tumor necrosis factor-α (TNF-α) in serum were measured by enzyme-linked immunosorbent assay. The Th17 and Treg subset distribution in spleen was determined by ?ow cytometry. Results Histopathological examination showed that LPS induced inflammatory cell infiltration in lung tissue, increased cell count and protein levels in BALF (P<0.05), and increased proportion of neutrophils and monocytes in the ALI mice. SB203580 significantly attenuated tissue injury of the lungs in LPS-induced ALI mice. Serum levels of IL-6 and TNF-α in the ALI group were significantly higher than those in the control group, and inflammatory cytokines were decreased after SB203580 intervention. Compared with the ALI group, the production of inflammatory cytokines associate with Th17, including IL-17, IL-23, RORγt was inhibited, and the production of cytokines associate with Treg, such as IL-10 and Foxp3 in lung tissue was increased in the intervention group in a concentration-dependent manner with SB203580. After SB203580 intervention, Th17/Treg ratio was significantly decreased compared with the LPS group (P<0.05). Conclusion p38MAPK inhibitor can reduce LPS-induced ALI by regulating the imbalance of Treg cells and Th17 cells.
Objective To compare the efficacy differences of immune checkpoint inhibitors (ICIs) in first-line versus subsequent-line immunotherapy for extensive-stage small-cell lung cancer (ES-SCLC). Methods Data on patients diagnosed with small cell lung cancer (SCLC) between January 2021 and December 2023 were retrospectively collected from West China Hospital of Sichuan University. According to the time at which ICIs, patients would be divided into first-line immunotherapy group and subsequent-line immunotherapy group. Multivariate Cox proportional hazards regression model analysis was used to analyze the influencing factors of overall survival (OS). Results A total of 166 patients were included. Among them, there were 121 cases in the first-line immunotherapy group and 45 cases in the subsequent-line immunotherapy group. The median follow-up of 24.07 (16.27, 31.70) months. 53 patients died in the first-line immunotherapy group and 28 in the subsequent-line immunotherapy group. The median OS of the two groups was 28.6 and 16.2 months, respectively, and the difference was statistically significant [log-rank P=0.021, 95% confidence interval (CI) (13.650, 27.090)]. There was also a significant difference in time to disease progression free survival between the two groups [9.67 and 7.90 months, respectively; Log-rank P=0.008, 95%CI (7.455, 9.745)]. There was no difference in OS between patients who continued and those who did not continue an ICI-containing regimen after disease progression on first-line immunotherapy [median OS of 37.1 and 24.8months for continuation of immunotherapy versus no immunotherapy, respectively; Log-rank P=0.600, 95%CI (14.953, 34.587)]. COX multifactorial regression analysis found that body mass index≥24 kg/m2 (P=0.014) and undergoing prophylactic cranial irradiation (P=0.036) reduced the risk of death. Conclusions ES-SCLC patients with first-line initial therapy using ICIs-containing drugs had better OS than those with ICIs in the subsequent-line, and re-selection of the same or different ICIs after progression of those who had used ICIs drugs in the first line did not improve survival.
